Answers are grounded in this paper and cite their sources.
Immunotherapy agents are now widely used in the treatment of metastatic melanoma. Immune‐related adverse events (irAEs) may occur, including cutaneous pathologies in 50% of patients. We report a case of Sweet syndrome (SS) in a patient who was prescribed ipilimumab and nivolumab for metastatic melanoma.
No takes yet. Share an insight, caveat, or question.
Barry et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: